Breathe Well Live Well
|
Positive results trial for new asthma treatment
Medical Xpress This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen reports positive Phase II asthma trial data Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Positive results in Southampton-led patient trial for new asthma treatment
Science Codex This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen reports positive Phase II asthma trial data Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Positive results in Southampton-led patient trial for new asthma treatment
EurekAlert (press release) This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Positive Phase II Asthma Clinical Trial Data
SYS-CON Media (press release) This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma … |
View full post on asthma – Google News
|
Biota Reports Positive Phase IIb Data For Asthmatic Patients With HRV Infection
NASDAQ The Phase II multicenter, randomized, double-blind, placebo controlled study in asthmatic adults with symptomatic, naturally acquired human rhinovirus infection was conducted over two consecutive seasons in 48 centers in the US Subjects received either … Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human … |
View full post on asthma – Google News
|
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human …
MarketWatch (press release) "While the clinical link between HRV infection and loss of asthma control is now widely accepted, Biota is the first company to evaluate the use of an antiviral to treat the infection in asthmatics. This has the potential to be of considerable benefit … |
View full post on asthma – Google News
|
Boston Scientific Welcomes Positive Private Insurance Coverage Decisions for …
Bradenton Herald "These coverage policies support the CMS payment decisions announced earlier this year and further confirm bronchial thermoplasty as a promising new advancement in the treatment of severe asthma." Bronchial thermoplasty delivered by the Alair System … |
View full post on asthma – Google News
|
Boston Scientific Welcomes Positive Private Insurance Coverage Decisions for …
MarketWatch (press release) "These coverage policies support the CMS payment decisions announced earlier this year and further confirm bronchial thermoplasty as a promising new advancement in the treatment of severe asthma." Bronchial thermoplasty delivered by the Alair System … |
View full post on asthma – Google News
|
Aerocrine: South Carolina Adopts Positive Coverage of Aerocrine's FeNo Testing …
Business Wire (press release) “FeNO testing is a significant advancement in managing the patient with asthma. Since the publication of the American Thoracic Guideline on FeNO, this test should be standard of care in every clinic managing asthma patients. South Carolina adopts positive coverage of Aerocrine's FeNO testing in … |
View full post on asthma – Google News
|
South Carolina adopts positive coverage of Aerocrine's FeNO testing in …
CisionWire (press release) Physicians use FeNO to assess eosinophilic airway inflammation, the primary underlying abnormality that affects the airways of individuals who have asthma. NIOX MINO is the only product of its kind currently on the market for assessing FeNO. |
View full post on asthma – Google News